

**Mouse Glucagon-Like Peptide-1 Receptor
Reporter Assay System
(GLP-1R)**

3x32 Assays in 96-well Plate Format
Product # M33001-32

▪


Technical Manual
(version 7.2i)

www.indigobiosciences.com

3006 Research Drive, Suite A1, State College, PA 16801, USA

Customer Service:
814-234-1919; FAX 814-272-0152
customerserv@indigobiosciences.com

Technical Service:
814-234-1919
techserv@indigobiosciences.com



Mouse GLP-1R Reporter Assay System 3x 32 Assays in 96-well Plate Format

I. Description	
▪ Background.....	3
▪ The Assay System.....	3
▪ The Assay Chemistry.....	4
▪ Preparation of Test Compounds.....	4
▪ Assay Scheme.....	5
▪ Assay Performance.....	6
II. Product Components & Storage Conditions	7
III. Materials to be Supplied by the User	7
IV. Assay Protocol	
▪ A word about <i>Inhibition</i> -mode assay setup.....	8
▪ <i>DAY 1 Assay Protocol</i>	8
▪ <i>DAY 2 Assay Protocol</i>	10
V. Related Products	11
VI. Citations	12
VII. Limited Use Disclosures	12
APPENDIX 1: Example Scheme for Serial Dilutions	13

I. Description

▪ **Background** ▪

This assay utilizes proprietary cells that provide constitutive expression of the **Mouse Glucagon-like Peptide-1 Receptor (mGLP-1R)**.

The GLP-1R belongs to a class B G protein-coupled Receptor (GPCR), which is activated by several forms of GLP-1^{1,2}. GLP-1 is the second incretin hormone identified in the intestinal epithelial endocrine L-cells, followed by gastric inhibitory polypeptide (GIP)³. GLP-1/GLP-1R mainly regulates insulin secretion in response to high blood glucose levels³. This receptor system plays a crucial role in energy homeostasis.

Upon the ligand binding of GLP-1, GLP-1R signals through G α s to drive an increase in intracellular cAMP via activation of adenylate cyclase (AC). This signaling pathway continues through the activation of protein kinase A (PKA) and exchange protein activated cAMP (EPAC) dependent mechanisms⁴. Ultimately, the signal transduction cascade stimulates the opening of calcium and cation channels to induce calcium influx, which promotes insulin secretion⁵. cAMP response binding element (CREB) is also activated by GLP-1R to induce the expression of insulin transcription factor in cAMP/PKA-dependent manner⁶.

Because of the significant role of GLP-1/GLP-1R as a key regulator of metabolism, several clinical trials have been attempted to develop therapies for patients with Type II diabetes. For example, GLP-1R agonists (GLP-1RAs) have been introduced as a novel class of therapeutic agent to manage glycemic control⁷.

▪ **The Assay System** ▪

INDIGO's Reporter Cells contains an engineered luciferase reporter gene functionally linked to tandem Cyclic AMP Response Elements (CRE) and a minimal promoter. Activated adenylate cyclase results in the production of cAMP, which binds the transcription factor CREB (cAMP Response Element-Binding Protein). Activated CREB binds to CRE sequences, seeding the formation of a complete transcription complex that drives luciferase gene expression. Quantifying relative changes in luciferase enzyme activity in the treated reporter cells relative to the untreated reporter cells provides a sensitive surrogate measure of drug-induced changes in mGLP-1R activity. Accordingly, the principal application of this reporter assay is in the screening of test compounds to quantify any functional activities, either activating or inhibitory, that they may exert against mGLP-1R. INDIGO's Reporter Cells are transiently transfected and prepared as cryopreserved stocks using a proprietary **CryoMite™** process. This cryo-preservation method allows for the immediate dispensing of healthy, division-competent reporter cells into assay plates. There is no need for intermediate treatment steps such as spin-and-rinse of cells, viability determinations or cell titer adjustments prior to assay setup.

INDIGO's assay kits provide the convenience of an all-inclusive cell-based assay system. In addition to mGLP-1R Reporter Cells, provided are two optimized media for use in recovering the cryopreserved cells and for diluting test samples, the reference activator GLP-1, Luciferase Detection Reagents, and a cell culture-ready assay plate.

▪ The Assay Chemistry ▪

INDIGO's receptor assay kits capitalize on the extremely low background, high-sensitivity, and broad linear dynamic range of bio-luminescence reporter gene technology.

Reporter Cells incorporate the cDNA encoding beetle luciferase, a 62 kD protein originating from the North American firefly (*Photinus pyralis*). Luciferase catalyzes the mono-oxidation of D-luciferin in a Mg^{+2} -dependent reaction that consumes O_2 and ATP as co-substrates to yield oxyluciferin, AMP, PP_i , CO_2 , and photon emission. Luminescence intensity of the reaction is quantified using a luminometer and is reported in terms of Relative Light Units (RLU's).

Assay kits feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.

▪ Preparation of Test Compounds ▪

Small molecule test compounds: Small-molecule test compounds are typically solvated in DMSO at high concentrations; ideally 1,000x-concentrated stocks relative to the highest desired treatment concentration in the assay. Using high-concentration stocks minimizes DMSO carry-over into the assay plates. Immediately prior to setting up an assay, the master stocks are serially diluted using one of two alternative strategies:

1.) As described in *Step 7* and depicted in Appendix 1 for the reference activator GLP-1 (a polypeptide), Compound Screening Medium (CSM) may be used directly as the diluent to prepare serial dilutions of test compounds to achieve the desired final assay concentration series.

Alternatively, if small-molecule test compound solubility is expected to be problematic, 2.) DMSO may be used to make serial dilutions, thereby generating 1,000x-concentrated stocks for each independent test concentration. Treatment media are then prepared using CSM to make final 1,000-fold dilutions of the prepared DMSO dilution series.

Regardless of the dilution method used, the final concentration of total DMSO carried over into assay wells should not exceed 0.4%. DMSO-induced cytotoxicity can be expected above 0.4%.

NOTE: CSM is formulated to help stabilize hydrophobic small molecule test compounds in the aqueous environment of the treatment media. Nonetheless, high concentrations of small organic molecules diluted in CSM may lack long-term stability and/or solubility, especially if further stored at low temperatures. Hence, it is recommended that compound dilutions are prepared in CSM immediately prior to assay setup and are then treated as 'single-use' reagents.

Protein samples (*e.g.*, antibodies or activator polypeptides): For protein test samples it is recommended to solvate the test materials in aqueous buffered solutions supplemented with carrier protein (*e.g.*, PBS + 0.1% BSA) at concentrations *no less* than 10x relative to the highest desired treatment concentration. The **GLP-1 stock** included with this kit is prepared in PBS + 0.1% BSA at a 100x-concentration relative to the highest recommended treatment (as depicted in APPENDIX 1).

▪ Assay Scheme ▪




Figure 1. Assay workflow. Reporter Cells are dispensed into the strip-wells (mounted into the assay plate frame), then incubated for 4-6 hours. Following the pre-incubation period, the culture media are discarded, and the prepared treatment media are added. Following a 22–24 hours treatment period the media are discarded, and Luciferase Detection Reagent is added. The intensity of light emission (in units of 'Relative Light Units'; RLU) from each assay well is quantified using a plate-reading luminometer.




Figure 2. Activation of Mouse GLP-1R. Activation assays were performed using the reference compounds Glucagon-like Peptide-1 (GLP-1 [7-36]; provided), Exendin-4 (48-86), Liraglutide, Semaglutide and Tirzepatide (all from Cayman Chemical, Ann Arbor, MI), GLP-1 (7-37) (R&D System, Minneapolis, MN), and Danuglipron (Adoq, Irvin, CA). Luminescence was quantified and values of average ($n=3$) relative light units (RLU), corresponding standard deviation (SD), Fold-Activation, and Z' ⁸ values were calculated. GraphPad Prism software was used to plot data using the least-squares method of non-linear regression for Fold-Activation vs. Log_{10} [Cmpd, nM], and to determine EC_{50} values.

II. Product Components & Storage Conditions

This Mouse GLP-1R Assay kit contains materials to perform three distinct groups of assays in a 96-well plate format. Reagents are configured so that each group will comprise 32 assays. If desired, however, reagents may be combined to perform either 64 or 96 assays.

Reporter cells are temperature sensitive! To ensure maximal viability the tube of cells must be maintained at -80°C until immediately prior to the rapid-thaw procedure described in Step 3 of this protocol.

Assay kits are shipped on dry ice. Upon receipt of the kit transfer it to -80°C storage. If you wish to first inspect and inventory the individual kit components be sure to first transfer and submerge the tube of reporter cells in dry ice.

The aliquot of Reporter Cells is provided as a single-use reagent. Once thawed, reporter cells can NOT be refrozen, nor can they be maintained in extended culture with any hope of retaining downstream assay performance. Therefore, extra volumes of these reagents should be discarded after assay setup.

The date of product expiration is printed on the Product Qualification Insert (PQI) enclosed with each kit.

<u>Kit Components</u>	<u>Amount</u>	<u>Storage Temp.</u>
▪ mGLP-1R Reporter Cells	3 x 0.6 mL	-80°C
▪ Cell Recovery Medium (CRM)	2 x 10.5 mL	-20°C
▪ Compound Screening Medium (CSM)	1 x 45 mL	-20°C
▪ Glucagon-like Peptide-1, (7-36) (5.0 µM in PBS+0.1% BSA)	1 x 30 µL	-20°C
▪ Detection Substrate (Note: contains DTT)	3 x 2.0 mL	-80°C
▪ Detection Buffer	3 x 2.0 mL	-20°C
▪ Plate frame	1	ambient
▪ Snap-in 8-well strips	12	ambient

III. Materials to be Supplied by the User

The following materials must be provided by the user, and should be made ready prior to initiating the assay procedure:

- dry ice bucket (*Step 2*)
- cell culture-rated laminar flow hood.
- 37°C, humidified 5% CO₂ incubator for mammalian cell culture.
- 37°C water bath.
- 70% alcohol wipes
- 8-channel electronic, repeat-dispensing pipettes & sterile tips
- disposable media basins, sterile.
- sterile multi-channel media basins (such as the Heathrow Scientific "Dual-Function Solution Basin"), or sterilized 96 deep-well blocks (*e.g.*, Axygen Scientific, #P-2ML-SQ-C-S), or appropriate similar vessel for generating dilution series of reference and test compound(s).
- plate-reading luminometer.
- *Optional*: clear 96-well assay plate, sterile, for viewing cells on *Day 2*.
- Plate-reading luminometer

IV. Assay Protocol

Please review the entire Assay Protocol before starting. Completing the assay requires an overnight incubation. *Steps 1-11* are performed on **Day 1**, requiring less than 2 hours of bench work and a 4-hour incubation step to complete. *Steps 12-17* are performed on **Day 2** and require less than 1 hour to complete.

▪ A word about inhibition-mode assay setups ▪

When setting up receptor inhibition assays, the Reporter Cells are co-treated with a fixed sub-maximal concentration (typically between EC₅₀ – EC₈₅) of the reference agonist AND varying concentrations of the test compound(s). This assay kit includes a 5.0 μM stock solution of **GLP-1 (7-36)**, a potent physiological activator of the GLP-1R, that may be used to set up inhibition-mode assays. ~0.800 nM of GLP-1 (7-36) approximates EC₇₀₋₈₀ in this assay. Hence, it is a suitable concentration of challenge agonist to use when screening test materials for inhibitory activities.

Add the challenge activator, GLP-1 (7-36), to a bulk volume of **CSM** at an EC₅₀ – EC₈₅ concentration. This medium is then used to prepare serial dilutions of test compounds to achieve the desired respective final assay concentrations. This is an efficient and precise method of setting up inhibition assays, and it is the method presented in *Step 7b* of this protocol.

DAY 1 Assay Protocol: All steps should be performed using aseptic technique.

1.) Remove the **2 tubes** of **Cell Recovery Medium (CRM)** from freezer storage, thaw and equilibrate to 37°C using a water bath.

2.) Rapid Thaw of the Reporter Cells: *First*, retrieve the two tubes of **CRM** from the 37°C water bath and sanitize their outside surfaces with a 70% ethanol swab.

Second, retrieve tubes of **Reporter Cells** from -80°C storage and place them directly into dry ice for transport to the laminar flow hood: 1 tube for 32 assay wells, 2 tubes for 64 assay wells, or 3 tubes for 96 assay wells. When ready to begin, transfer the tube(s) of reporter cells into a rack and, *without delay*, perform a rapid thaw of the frozen cells by transferring **6.4 ml** of pre-warmed CRM into each tube of frozen cells. Recap the tube of Reporter Cells and immediately place it in a 37°C water bath for 5 - 10 minutes. The resulting volume of cell suspension will be **7.0 ml** per tube.

Third, work in the cell culture hood to *carefully* mount four sterile 8-well strips into the blank assay plate frame. Strip-wells are fragile. Note that they have keyed ends (square and round), hence, they will fit into the plate frame in only one orientation.

3.) Retrieve the tube of Reporter Cell Suspension from the water bath and sanitize the outside surface with a 70% alcohol swab.

4.) If more than one tube of Reporter cells was thawed, combine them and gently invert several times to gain a homogenous cell suspension. Dispense **200 μl / well** of cell suspension into the assay plate.

NOTE 4.1: If INDIGO's Live Cell Multiplex Assay is to be incorporated, a minimum of 3 'cell blank' wells (meaning cell-free but containing CSM) must be included in the assay plate to allow quantification of plate-specific fluorescence background (refer to the LCMA Technical Manual).

NOTE 4.2: Increased well-to-well variation (= increased standard deviation!) will occur if care is not taken to prevent cells from settling in the reservoir during the dispensing period. Likewise, take care to ensure precision in dispensing exact volumes across the assay plate.

(continued)

NOTE 4.3: Users sometimes wish to examine the reporter cells using a microscope. If so, the extra volume of cell suspension provided with each kit may be dispensed into a clear 96-well assay plate. Continue to process this plate in an identical manner to the white assay plate.

5.) Pre-incubate reporter cells. Place the assay plate into a cell culture incubator (37°C, ≥ 70% humidity, 5% CO₂) for 4 - 6 hours.

6.) Near the end of the pre-incubation period remove **Compound Screening Medium (CSM)** from freezer storage and thaw in a 37°C water bath.

7.) Prepare the Test Compound and Reference Compound treatment media. As discussed in “*Preparation of Test Compounds*” (pg. 4), use **CSM** to prepare an appropriate dilution series of the reference and test compound stocks. In *Step 9*, the prepared treatment media will be dispensed at **200 µl / well** into the assay plate. Manage dilution volumes carefully; this assay kit provides **45 ml** of CSM.

NOTE: Total DMSO, or any other organic solvent, carried over into assay reactions should not exceed 0.4%.

a. Activation-mode assays. This assay kit includes a concentrated stock (5.0 µM) of the polypeptide **GLP-1 (7-36)** prepared in PBS+0.1% BSA. The following 7-point treatment series, with concentrations generated using serial 4-fold dilutions, provides a complete dose-response: 50.0, 10.0, 2.00, 0.400, 0.0800, 0.0160, and 0.00320 nM. **APPENDIX 1** provides guidance for generating such a dilution series. Always include 'no treatment' (or 'vehicle only') controls.

~ or ~

b. Inhibition-mode assays. When setting up inhibition assays, first supplement a bulk volume of CSM with the challenge activator **GLP-1 (7-36)** to achieve an EC₅₀ – EC₈₀ concentration (refer to “*A word about antagonist-mode assay setup*”, pg. 8). The supplemented CSM is then used to generate dilutions of test compound stocks to achieve the desired series of treatment concentrations.

8.) At the end of the cell pre-incubation period, discard the culture media. Because the assay plate is composed of a frame with snap-in strip-wells, the practice of physically ejecting media is NOT advised. Complete removal of the media is efficiently performed by tilting the plate on edge and aspirating media using either a single-tip, or an 8-pin manifold (*e.g.*, Wheaton Science Microtest Syringe Manifold, # 851381) affixed to a vacuum-trap apparatus. Do *not* touch the well bottom or run the tip of the aspiration device around the bottom circumference of the assay well. Such practices will result in destruction of the cells and greatly increased well-to-well variability.

9.) Dispense **200 µl / well** of each prepared treatment media into the assay plate.

10.) Transfer the assay plate into a cell culture incubator for 22 - 24 hours.

NOTE: Ensure a high-humidity (≥70%) environment within the cell culture incubator. This is critical to prevent the onset of deleterious "edge-effects" in the assay plate.

11.) For greater convenience on *Day 2*, retrieve the appropriate number of vials of **Detection Substrate and Detection Buffer** from freezer storage and place them in a dark refrigerator (4°C) to thaw overnight.

DAY 2 Assay Protocol: Subsequent manipulations do *not* require special regard for aseptic technique and may be performed on a bench top or in a **fume hood**.

12.) Approximately 30 minutes before intending to quantify receptor activity, remove **Detection Substrate** and **Detection Buffer** from the refrigerator and place them in a low-light area so that they may equilibrate to room temperature.

NOTE: Do NOT actively warm Detection Substrate above room temperature. If these solutions were not allowed to thaw overnight at 4°C, a room temperature water bath may be used to expedite thawing.

13.) Set the plate-reader to "luminescence" mode. Program the instrument to perform a single 5 second "plate shake" prior to reading the first assay well. Read time is set to 0.5 second (500 mSec) per well, *or less*.

14.) Immediately before proceeding to *Step 15*: To read 32 assay wells, transfer the entire volume of 1 vial of Detection Buffer into 1 vial of Detection Substrate, thereby generating a 4 ml volume of **Luciferase Detection Reagent (LDR)**. Mix *gently* to avoid foaming.

NOTE: 'Detection Substrate' contains a high concentration of DTT, which produces a strong odor that some users may find objectionable. It is advised to work in a **fume hood** when preparing LDR, and subsequently when dispensing it into the assay plate and throughout the following 'plate rest' period (*Step 16*).

15.) Following 22 - 24 hours incubation in treatment media, remove media contents from each well of the assay plate (as before in *Step 8*).

16.) Add 100 µl of the prepared **LDR** into all wells of the assay plate. Allow the assay plate to rest at room temperature for 5 – 10 minutes following the addition of LDR. Do not shake the assay plate during this period.

17.) Quantify luminescence.

18.) Data analyses.

V. Related Products

<i>Product No.</i>	<i>Product Descriptions</i>
Mouse GLP-1R Assays	
M33001-32	Mouse GLP-1R Reporter Assay System 3x 32 assays in 8-well strips (96-well plate format)
M33001	Mouse GLP-1R Reporter Assay System 1x 96-well format assay
Bulk volumes of Mouse GLP-1R Assay Reagents may be custom manufactured to accommodate any scale of HTS. Please Inquire.	

<i>Product No.</i>	<i>Product Descriptions</i>
Human GLP-1R Assays	
IB33001-32	Human GLP-1R Reporter Assay System 3x 32 assays in 8-well strips (96-well plate format)
IB33001	Human GLP-1R Reporter Assay System 1x 96-well format assay
IB33002	Human GLP-1R Reporter Assay System 1x 384-well format assays

Human GIPR Assays	
IB38001	Human GIPR Reporter Assay System 1x 96-well format assay
IB38002	Human GIPR Reporter Assay System 1x 384-well format assays

LIVE Cell Multiplex (LCM) Assay	
LCM-01	Reagent volumes sufficient to perform 96 Live Cell Assays
LCM-05	Reagent in 5x bulk volume to perform 480 Live Cell Assays contained in 5 x 96-well assay plates
LCM-10	Reagent in 10x bulk volume to perform 960 Live Cell Assays contained in 10 x 96-well assay plates

INDIGlo Luciferase Detection Reagent	
LDR-10, -25, -50, -500	INDIGlo Luciferase Detection Reagents available in 10 mL, 25 mL, 50 mL, 500 mL, or custom volumes.

Please refer to INDIGO Biosciences website for updated product offerings.

www.indigobiosciences.com

VI. Citations

- ¹ Thorens B (1992) Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. PNAS **89**: 8641-8645.
- ² Kreymann B et al. (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-1304.
- ³ Schmidt WE et al (1985) Glucagon -like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28: 704-707.
- ⁴ Drucker DJ et al (1987) Glucagon-like peptide-1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. PNAS 84: 3434-3438.
- ⁵ Britsch S et al (1995) Glucagon-like peptide-1 modulates Ca^{2+} current but not K^{+} ATP current in intact mouse pancreatic B-cells. Biochem. Biophys. Res. Commun 207: 33-39.
- ⁶ Wang X et al (2001) Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein transcription factor from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142: 1820-1827.
- ⁷ Htike ZZ et al (2016) Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individual care. The British Journal of Diabetes 16; 128-137.
- ⁸ Zhang JH, *et al.* (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen.:**4**(2), 67-73.
$$Z' = 1 - [3*(SD^{Ref EC100} + SD^{Untreated}) / (RLU^{Ref EC100} - RLU^{Untreated})]$$

VII. Limited Use Disclosures

Products commercialized by INDIGO Biosciences, Inc. are for RESEARCH PURPOSES ONLY – not for therapeutic, diagnostic, or contact use in humans or animals.

“CryoMite” is a Trademark TM of INDIGO Biosciences, Inc. (State College, PA, USA)

Product prices, availability, specifications, and claims are subject to change without prior notice.

Copyright © INDIGO Biosciences, Inc. (State College, PA, USA). All Rights Reserved.

APPENDIX 1

Example scheme for the serial dilution of the reference agonist GLP-1 (7-36) and the setup of an mGLP-1R dose-response assay.

